These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22061182)

  • 1. Non-vision adverse events with vigabatrin therapy.
    Walker SD; Kälviäinen R
    Acta Neurol Scand Suppl; 2011; (192):72-82. PubMed ID: 22061182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential for vigabatrin-induced intramyelinic edema in humans.
    Cohen JA; Fisher RS; Brigell MG; Peyster RG; Sze G
    Epilepsia; 2000 Feb; 41(2):148-57. PubMed ID: 10691111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing.
    Carmant L
    Acta Neurol Scand Suppl; 2011; (192):36-47. PubMed ID: 22061179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Balancing clinical benefits of vigabatrin with its associated risk of vision loss.
    Pellock JM
    Acta Neurol Scand Suppl; 2011; (192):83-91. PubMed ID: 22061183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vigabatrin therapy for refractory complex partial seizures: review of clinical trial experience in the United States.
    Faught E
    Acta Neurol Scand Suppl; 2011; (192):29-35. PubMed ID: 22061178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding and interpreting vision safety issues with vigabatrin therapy.
    Plant GT; Sergott RC
    Acta Neurol Scand Suppl; 2011; (192):57-71. PubMed ID: 22061181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebral MRI abnormalities associated with vigabatrin therapy.
    Pearl PL; Vezina LG; Saneto RP; McCarter R; Molloy-Wells E; Heffron A; Trzcinski S; McClintock WM; Conry JA; Elling NJ; Goodkin HP; de Menezes MS; Ferri R; Gilles E; Kadom N; Gaillard WD
    Epilepsia; 2009 Feb; 50(2):184-94. PubMed ID: 18783433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry.
    Pellock JM; Faught E; Foroozan R; Sergott RC; Shields WD; Ziemann A; Lee D; Dribinsky Y; Torri S; Othman F; Isojarvi J
    Epilepsy Behav; 2016 Jul; 60():174-180. PubMed ID: 27208827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy.
    Wheless JW; Carmant L; Bebin M; Conry JA; Chiron C; Elterman RD; Frost M; Paolicchi JM; Donald Shields W; Thiele EA; Zupanc ML; Collins SD
    Epilepsia; 2009 Feb; 50(2):195-205. PubMed ID: 19054414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vigabatrin therapy for refractory complex partial seizures: review of major European trials.
    Ben-Menachem E; Sander JW
    Acta Neurol Scand Suppl; 2011; (192):16-28. PubMed ID: 22061177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin.
    Sergott RC; Westall CA
    Acta Neurol Scand Suppl; 2011; (192):48-56. PubMed ID: 22061180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile.
    Camposano SE; Major P; Halpern E; Thiele EA
    Epilepsia; 2008 Jul; 49(7):1186-91. PubMed ID: 18479386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group.
    Bruni J; Guberman A; Vachon L; Desforges C
    Seizure; 2000 Apr; 9(3):224-32. PubMed ID: 10777431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A risk-benefit assessment of vigabatrin in the treatment of neurological disorders.
    Srinivasan J; Richens A
    Drug Saf; 1994 May; 10(5):395-405. PubMed ID: 8037889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vigabatrin-induced MRI changes associated with extrapyramidal symptoms in a child with infantile spasms.
    Schonstedt V; Stecher X; Venegas V; Silva C
    Neuroradiol J; 2015 Oct; 28(5):515-8. PubMed ID: 26306928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vigabatrin.
    French JA
    Epilepsia; 1999; 40 Suppl 5():S11-6. PubMed ID: 10530689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological evidence of vacuolar myelinopathy in a child following vigabatrin administration.
    Horton M; Rafay M; Del Bigio MR
    J Child Neurol; 2009 Dec; 24(12):1543-6. PubMed ID: 19773459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral toxicity of vigabatrin in immature rats: characterization of intramyelinic edema.
    Walzer M; Bekersky I; Wanaski S; Collins S; Jortner B; Patterson R; Garman R; Sagar S; Tolbert D
    Neurotoxicology; 2011 Dec; 32(6):963-74. PubMed ID: 21473881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.
    Grant SM; Heel RC
    Drugs; 1991 Jun; 41(6):889-926. PubMed ID: 1715266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. The Canadian Vigabatrin Study Group.
    Guberman A; Bruni J
    Seizure; 2000 Mar; 9(2):112-8. PubMed ID: 10845734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.